Engimmune Therapeutics strikes ‘fast-forward’ micro-fluidics collaboration with Swiss innovator CSEM
- Collaboration with CSEM will speed up identification of suitable soluble TCR candidates
- Engimmune’s executive team will be presenting at Biotech Showcase in San Francisco in January
Basel, Switzerland, December 13, 2023 – Engimmune Therapeutics AG (“Engimmune”), a world-class developer of soluble T-cell receptor drugs (‘TCRs’) to treat solid tumours, is pleased to announce that it has entered into a collaboration with the Swiss Technology Innovation Center CSEM to accelerate the identification of safe and effective drugs using Engimmune’s unique platform.
